Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | VCAM1 | P19320 | 14/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | MMP8 | P22894 | 1/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.36 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.36 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6961763 | 0.88 | TDP1 (0.49) | TDP1VCAM1ALDH1A1TSHRMAPK1 | |
| SCHEMBL5711756 | 0.80 | TDP1 (0.46) | TDP1ALDH1A1TSHRMAPK1MAPT | |
| SCHEMBL4301275 | 0.77 | VCAM1 (0.49) | VCAM1ALDH1A1POLB | |
| SCHEMBL5906064 | 0.77 | TSHR (0.47) | VCAM1ALDH1A1TSHRMAPK1MAPT | |
| SCHEMBL273093 | 0.76 | TDP1 (0.60) | TDP1VCAM1ALDH1A1TSHRMAPK1 | |
| SCHEMBL6641853 | 0.75 | TSHR (0.41) | TDP1ALDH1A1TSHRMAPK1MAPT | |
| SCHEMBL6640062 | 0.74 | TUBB4A (0.43) | TDP1ALDH1A1MAPK1MAPT | |
| SCHEMBL278504 | 0.74 | TDP1 (0.62) | TDP1VCAM1ALDH1A1TSHRMAPK1 | |
| SCHEMBL2474011 | 0.74 | TDP1 (0.53) | TDP1VCAM1ALDH1A1TSHRMAPK1 | |
| SCHEMBL8562208 | 0.73 | TSHR (0.43) | VCAM1ALDH1A1TSHRMAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9067944-B2 | Process for the preparation of anagrelide and analogues thereof | SHIRE LLC (US) | 2015-06-30 | — | — | US | disclosed |
| US-9067944-B2 | Process for the preparation of anagrelide and analogues thereof | SHIRE LLC (US) | 2015-06-30 | — | — | US | disclosed |
| US-8530651-B2 | Process for the preparation of anagrelide and analogues | SHIRE LLC (US) | 2013-09-10 | — | — | US | disclosed |
| US-8530651-B2 | Process for the preparation of anagrelide and analogues | SHIRE LLC (US) | 2013-09-10 | — | — | US | disclosed |
| US-20130211083-A1 | PROCESS FOR THE PREPARATION OF ANAGRELIDE AND ANALOGUES THEREOF | SHIRE LLC (US) | 2013-08-15 | — | — | US | disclosed |
| US-20130211083-A1 | PROCESS FOR THE PREPARATION OF ANAGRELIDE AND ANALOGUES THEREOF | SHIRE LLC (US) | 2013-08-15 | — | — | US | disclosed |
| US-8304420-B2 | prodrug of platelet lowering agent anagrelide, especially 3-and 5-substituted analogues with reduced potential for cardiovascular side-effects and better absorption from the GI tract; imidazo[2,1-b]quinazolin-2-one derivatives; megakaryocytopoeisis inhibitor; anticoagulant, antiproliferative agents | SHIRE LLC (US) | 2012-11-06 | — | — | US | disclosed |
| US-20110263850-A1 | PROCESS FOR THE PREPARATION OF ANAGRELIDE AND ANALOGUES | SHIRE LLC (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110263850-A1 | PROCESS FOR THE PREPARATION OF ANAGRELIDE AND ANALOGUES | SHIRE LLC (US) | 2011-10-27 | — | — | US | disclosed |
| WO-2010070318-A1 | PROCESS FOR THE PREPARATION OF ANAGRELIDE AND ANALOGUES | SHIRE LLC (US) | 2010-06-24 | — | — | WO | disclosed |
| US-20080176875-A1 | SUBSTITUTED QUINAZOLINES | SHIRE LLC (US) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176875-A1 | SUBSTITUTED QUINAZOLINES | MPL, ABL1, PDGFRA | TDP1 1109/4885VCAM1 844/4885ALDH1A1 1261/4885 |
| US-20110263850-A1 | PROCESS FOR THE PREPARATION OF ANAGRELIDE AND ANALOGUES | CIAPIN1, QDPR, THPO | TDP1 555/4885VCAM1 873/4885ALDH1A1 900/4885 |
| US-20130211083-A1 | PROCESS FOR THE PREPARATION OF ANAGRELIDE AND ANALOGUES THEREOF | CIAPIN1, QDPR, CYP51A1 | TDP1 1113/4885VCAM1 2199/4885ALDH1A1 1392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.